

PROXY FORM

The undersigned
in his/her/its capacity as a shareholder

In the case of a natural person:

Surname, Name:
Address:
Birth date:
Email:
Phone number:

In the case of a legal entity:

Company name:
Registered office:
Registration authority:
Registration number:
Authorised representative:
Email:
Phone number:

(hereinafter the "**Shareholder**")

being the owner on April 13, 2026 at 24:00 (midnight) (Luxembourg time) ("**Record Date**") of:

_____ dematerialised shares (*indicate number of dematerialised shares held*)

_____ registered shares (*indicate number of registered shares held*)

issued by LUXEMPART, a public limited company (*société anonyme*), governed by Luxembourg law, having its registered office at 12, rue Léon Laval, L-3372 Leudelange, registered with the Luxembourg Trade and Companies Register under number B 27.846 (the "**Company**")

irrevocably designates:

In the case that the proxyholder is a natural person:

Surname, Name:
Address:
Birth date:
Email:
Phone number:

In the case that the proxyholder is a legal entity:

Company name:
Registered office:
Registration authority:
Registration number:
Authorised representative:
Email:
Phone number:

(hereinafter the “**Proxyholder**”)

as his/her/its agent with full power of substitution and the power to act individually in order to participate in the name and on behalf of the Shareholder and to exercise the rights of the Shareholder for the total number of shares referred to above or, failing that, for the total number of shares whose holding is established on the Record Date,

to the Annual Shareholders' Meeting of April 27, 2026 of the Company convened for 11:00 a.m. (Luxembourg time) to be held at the registered office of the Company (the “**Meeting**”), on the following agenda, or to any subsequent meeting with the same agenda if the former is adjourned or postponed:

AGENDA

1. Presentation of the main events during the financial year 2025 and of the outlook
2. Presentation of the financial results for the year 2025
3. Presentation of the management report for the financial year 2025
4. Presentation of the audit reports
5. Report on any conflict of interest of a financial nature
6. Approval of the consolidated financial statements for the financial year 2025
7. Approval of the statutory annual accounts for the financial year 2025

8. Allocation of the result of the financial year 2025 including the declaration of a dividend
9. Presentation of the remuneration of the directors and executive committee members in 2025 and consultative vote on the 2025 remuneration report
10. Discharge of the directors for the performance of their duties during the financial year 2025
11. Renewal of the mandate of Mr. Xavier Coirbay as a director for a 3-year period
12. Renewal of the mandate of Mr. Frank Donck as a director for a 3-year period
13. Renewal of the mandate of LIDA SAS (with Mr. Gregoire Chertok as permanent representative) as a director for a 1-year period
14. Renewal of the mandate of Mr. Owen Tesch as a director for a 3-year period
15. Renewal of the mandate of Mr. Jürgen Vanselow as a director for a 3-year period
16. Appointment of Mrs. Andrea Davis as a director for a 3-year period
17. Presentation of the revised executive remuneration policy and consultative vote
18. Approval of the remuneration of the directors for the financial year 2026
19. Renewal of the mandate of the independent auditor for the financial year 2026
20. Miscellaneous

The Shareholder hereby confirms that on the Record Date, the exercise of the voting rights of the Shareholder is not suspended and that they have not been waived in whole or in part by the Shareholder.

TYPE OF PROXY

(check the appropriate box of (i) Option 1: Discretionary Mandate, and check the appropriate sub-option box within Option 1 or (ii) Option 2: Voting Instructions, and check the appropriate sub-option box within Option 2):

OPTION 1 DISCRETIONARY MANDATE: The Shareholder grants full authority and irrevocably gives power to the Proxyholder named herein above to vote for or against or abstain from voting on the proposed resolutions on the afore-mentioned agenda in the name and on behalf of the Shareholder as he/she/it sees fit.

If amendments and/or any new resolutions are validly presented at the Meeting:

SUB-OPTION 1A: The Shareholder grants full authority and irrevocably gives power to the Proxyholder to vote for or against or abstain from voting in the name and on behalf of the Shareholder as he/she/it sees fit on any amendments and/or on any new resolutions validly presented at the Meeting.

OR

SUB-OPTION 1B: The Shareholder intends to complete and sign an updated proxy form to be provided by the Company along with the agenda of the Meeting as updated to include any amendments and/or any new resolutions; upon receipt of such completed and signed updated proxy form by the Company, this proxy form shall cease to be valid.

OPTION 2 VOTING INSTRUCTIONS: By signing this proxy form, the Shareholder grants full authority and irrevocably gives power to the Proxyholder to vote for or against or abstain from voting at the Meeting in accordance with the voting instructions as indicated in the enclosed Appendix.

Please refer to the Appendix and indicate with an "X" in the appropriate box. Voting instructions are considered irrevocable and final on April 22, 2026. If neither the meaning of a voting instruction nor abstention is mentioned, the proxy will be assumed to have been instructed to vote in favour of the proposed resolution in question.

If amendments and/or any new resolutions are validly presented at the Meeting:

SUB-OPTION 2A: The Shareholder grants full authority and irrevocably gives a power to the Proxyholder to vote for or against or abstain from voting in the name and on behalf of the Shareholder as he/she/it sees fit on any amendments and/or on any new resolutions validly presented at the Meeting.

OR

SUB-OPTION 2B: The Shareholder intends to complete and sign an updated proxy form to be provided by the Company along with the agenda of the Meeting as updated to include any amendments of the agenda and/or any new resolutions validly presented at the Meeting, and upon receipt of such completed and signed updated proxy form by the Company, this proxy form shall cease to be valid.

DOCUMENTS TO BE ATTACHED

This proxy form is only valid if dated, signed and is accompanied by (if applicable) a Certificate (as defined below) and a copy of your valid identity document or in case the Proxyholder is a legal entity, the natural person(s) representing such entity who wishes to represent the Proxyholder at the Meeting must attach to this form the original or a copy of his or her power of representation, such as a general or special power of attorney or a recent extract from the commercial register indicating the identity of the proxyholder's legal representatives.

SENDING THE FORM

This proxy form, completed and signed, together with the documents to be attached thereto, shall be sent to the Company by post or electronically (e-mail: investors@luxempart.lu, postal address: LUXEMPART, attn. Legal Department, 12 rue Léon Laval, L-3372 Leudelange). The Company must have received this proxy form completed and signed together with the documents to be attached thereto, by April 22, 2026, at the latest.

We remind you that :

- shareholders wishing to participate in the Meeting must send their notice of participation in the Meeting (a form of which is provided to them by the Company) to the Company by post or e-mail (e-mail: investors@luxempart.lu, postal address: LUXEMPART, attn. Legal Department, 12

rue Léon Laval, L-3372 Leudelange) at the latest on the Record Date (April 13, 2026 at 24:00 (midnight) Luxembourg time);

- registered shareholders must be entered in the register of registered shares on the Record Date;
- shareholders holding dematerialised shares must have a certificate drawn up by their custodian, establishing their status as shareholder and certifying the number of dematerialised shares registered in their name on April 13, 2026 at 24:00 (midnight) (Luxembourg time) (the “**Certificate**”) and the Company must have received this certificate at the latest on April 22, 2026 by postal or electronic means (e-mail: investors@luxempart.lu, postal address: LUXEMPART, attn. Legal Department, 12 rue Léon Laval, L-3372 Leudelange); and
- only persons who are shareholders on the Record Date will be entitled to participate and exercise their rights at the Meeting.

GENERAL PROVISIONS

This proxy form is valid until June 30, 2026 inclusive.

(check if appropriate) The Shareholder agrees to indemnify and save harmless the Proxyholder, and to fully indemnify and save harmless the Proxyholder from and against all costs, claims, expenses, losses, liabilities and damages incurred by the Proxyholder in connection with the powers conferred upon the Proxyholder in this proxy form or in the exercise of any of the powers conferred, or purported to be conferred, upon the Proxyholder by this proxy form.

This form of proxy shall be governed by the laws of Luxembourg and any dispute relating thereto shall be submitted exclusively to the competent courts of Luxembourg City, Grand Duchy of Luxembourg.

Done at (*place*) _____, on (*date*) _____ 2026.

Signature: _____

(First name, Last name of the shareholder) _____

Appendix

Option 2: Voting Instructions

Proposed resolutions	Voting instructions (Check the appropriate box, if applicable)
<p>1. Presentation of the main events during the financial year 2025 and of the outlook</p> <p><i>A presentation of the main events during the financial year 2025 and of the outlook for the Company and the group will be given during the General Meeting.</i></p> <p><i>This item does not call for resolution.</i></p>	<p><i>no resolution</i></p>
<p>2. Presentation of the financial results for the year 2025</p> <p><i>A presentation of the financial results for the financial year 2025 will be given during the General Meeting.</i></p> <p><i>This item does not call for resolution.</i></p>	<p><i>no resolution</i></p>
<p>3. Presentation of the management report for the financial year 2025</p> <p><i>The management report of the Board of Directors on the annual and consolidated financial statements of the Company for the financial year 2025 will be presented during the General Meeting.</i></p> <p><i>This item does not call for resolution.</i></p>	<p><i>no resolution</i></p>
<p>4. Presentation of the audit reports</p> <p><i>A presentation of the auditor's reports on the annual accounts and the consolidated accounts of the Company for the financial year 2025 will be given during the General Meeting.</i></p> <p><i>This item does not call for resolution.</i></p>	<p><i>no resolution</i></p>

Proposed resolutions	Voting instructions (Check the appropriate box, if applicable)
<p>5. Report on any conflict of interest of a financial nature</p> <p><i>A report on any transaction decided by the Board of Directors in 2025 and until the date of the General Meeting in which a director had a financial interest opposite to that of the Company will be made during the General Meeting.</i></p> <p><i>A report on any transaction decided by the Group Executive Committee in 2025 and until the date of the General Meeting in which a member of that committee had a financial interest opposite to that of the Company will be made during the General Meeting.</i></p> <p><i>This item does not call for resolution.</i></p>	<p style="text-align: center;"><i>no resolution</i></p>
<p>6. Approval of the consolidated financial statements for the financial year 2025</p> <p><i>Proposed resolution</i></p> <p><i>The Board of Directors proposes to the General Meeting to approve the consolidated financial statements of the Company for the financial year 2025 in the form included in the documents presented to the General Meeting.</i></p>	<p style="text-align: center;">in favour <input type="checkbox"/> against <input type="checkbox"/> abstain <input type="checkbox"/></p>
<p>7. Approval of the statutory annual accounts for the financial year 2025</p> <p><i>Proposed resolution</i></p> <p><i>The Board of Directors proposes to the General Meeting to approve the statutory annual accounts of the Company for the financial year 2025 in the form included in the documents presented to the General Meeting.</i></p>	<p style="text-align: center;">in favour <input type="checkbox"/> against <input type="checkbox"/> abstain <input type="checkbox"/></p>

Proposed resolutions	Voting instructions (Check the appropriate box, if applicable)		
<p>8. Allocation of the result of the financial year 2025 including the declaration of a dividend</p> <p>Proposed resolution</p> <p><i>The Board of Directors proposes to the General Meeting to approve the allocation of the result of the Company for the financial year 2025 and to declare a dividend as indicated in the table below.</i></p>	<p>in favour <input type="checkbox"/> against <input type="checkbox"/> abstain <input type="checkbox"/></p>		
<table border="0" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 70%;">Allocation of the result</td> <td style="text-align: right;">EUR</td> </tr> </table>		Allocation of the result	EUR
Allocation of the result	EUR		
Profit for the financial year 2025	66,873,155.97		
Profit brought forward at 31/12/2025	1,002,426,156.10		
Total amount available for allocation	1,069,299,312.07		
<p>Allocation:</p>			
- Payment of a dividend of 2.56 EUR/share to 20,156,318 shares (20,700,000 shares less 543,682* treasury shares)	51,600,174.08		
- Profit brought forward	1,017,699,137.99		
Total amount allocated	1,069,299,312.07		
<p><i>* THE FINAL AGGREGATE DIVIDEND WILL DEPEND ON THE NUMBER OF TREASURY SHARES HELD ON THE DIVIDEND RECORD DATE.</i></p>			

Proposed resolutions	Voting instructions (Check the appropriate box, if applicable)
<p>9. Presentation of the remuneration of the directors and executive committee members in 2025 and consultative vote on the 2025 remuneration report</p> <p><i>A presentation of the remuneration of the directors (including the managing director) and executive committee members of the Company in 2025 will be made during the General Meeting.</i></p> <p>Proposed resolution</p> <p><i>The Board of Directors proposes to the General Meeting to approve by way of consultative vote the annual report on the remuneration of the directors (including the managing director) and the members of the executive committee of the Company for the financial year 2025, as set out in the annual financial report 2025 of the Company.</i></p>	<p>in favour <input type="checkbox"/> against <input type="checkbox"/> abstain <input type="checkbox"/></p>
<p>10. Discharge of the directors for the performance of their duties during the financial year 2025</p> <p>Proposed resolution</p> <p><i>The Board of Directors proposes to the General Meeting to grant discharge to the directors of the Company for the performance of their duties during the financial year 2025.</i></p>	<p>in favour <input type="checkbox"/> against <input type="checkbox"/> abstain <input type="checkbox"/></p>
<p>11. Renewal of the mandate of Mr. Xavier Coirbay as a director for a 3-year period</p> <p>Proposed resolution</p> <p><i>The Board of Directors proposes to the General Meeting to renew the mandate of Mr. Xavier Coirbay as director of the Company for a term of 3 years ending on the date of the annual general meeting to be held in 2029.</i></p>	<p>in favour <input type="checkbox"/> against <input type="checkbox"/> abstain <input type="checkbox"/></p>

Proposed resolutions	Voting instructions (Check the appropriate box, if applicable)
<p align="center">12. Renewal of the mandate of Mr. Frank Donck as a director for a 3-year period</p> <p>Proposed resolution</p> <p><i>The Board of Directors proposes to the General Meeting to renew the mandate of Mr. Frank Donck as director of the Company for a term of 3 years ending on the date of the annual general meeting to be held in 2029.</i></p>	<p align="center">in favour <input type="checkbox"/> against <input type="checkbox"/> abstain <input type="checkbox"/></p>
<p align="center">13. Renewal of the mandate of LIDA SAS (with Mr. Gregoire Chertok as permanent representative) as a director for a 1-year period</p> <p>Proposed resolution</p> <p><i>The Board of Directors proposes to the General Meeting to renew the mandate of LIDA SAS (with Mr. Gregoire Chertok as permanent representative) as director of the Company for a term of 1 year ending on the date of the annual general meeting to be held in 2027.</i></p>	<p align="center">in favour <input type="checkbox"/> against <input type="checkbox"/> abstain <input type="checkbox"/></p>
<p align="center">14. Renewal of the mandate of Mr. Owen Tesch as a director for a 3-year period</p> <p>Proposed resolution</p> <p><i>The Board of Directors proposes to the General Meeting to renew the mandate of Mr. Owen Tesch as director of the Company for a term of 3 years ending on the date of the annual general meeting to be held in 2029.</i></p>	<p align="center">in favour <input type="checkbox"/> against <input type="checkbox"/> abstain <input type="checkbox"/></p>

Proposed resolutions	Voting instructions (Check the appropriate box, if applicable)
<p align="center">15. Renewal of the mandate of Mr. Jürgen Vanselow as a director for a 3-year period</p> <p>Proposed resolution</p> <p><i>The Board of Directors proposes to the General Meeting to renew the mandate of Mr. Jürgen Vanselow as director of the Company for a term of 3 years ending on the date of the annual general meeting to be held in 2029.</i></p>	<p align="center">in favour <input type="checkbox"/> against <input type="checkbox"/> abstain <input type="checkbox"/></p>
<p align="center">16. Appointment of Mrs. Andrea Davis as a director for a 3-year period</p> <p>Proposed resolution</p> <p><i>The Board of Directors proposes to the General Meeting to appoint Mrs. Andrea Davis as director of the Company for a term of 3 years ending on the date of the annual general meeting to be held in 2029.</i></p> <p><i>The appointment of Mrs. Davis would bring to the Board of Directors both extensive executive leadership experience, including CEO roles across multiple sectors, and more than 10 years of private equity experience (as Managing Director, European Private Equity at Investcorp). In addition, as an experienced board member, she will further strengthen the Board’s private equity expertise following the departure of Mrs Ashton, while also contributing a valuable UK-oriented perspective alongside the Board’s continental European background.</i></p> <p><i>She holds an MBA from London Business School and a Bachelor of Science in Computer Science & Electronics from Loughborough University (UK).</i></p> <p><i>Mrs. Davis meets the independence criteria defined in the corporate governance charter of the Company.</i></p>	<p align="center">in favour <input type="checkbox"/> against <input type="checkbox"/> abstain <input type="checkbox"/></p>

Proposed resolutions	Voting instructions (Check the appropriate box, if applicable)
<p>17. Presentation of the revised executive remuneration policy and consultative vote</p> <p><i>A presentation of the revised executive remuneration policy will be made during the General Meeting.</i></p> <p>Proposed resolution</p> <p><i>The Board of Directors proposes to the General Meeting to approve by way of consultative vote the revised remuneration policy for the members of management and the members of the Board of Directors of the Company.</i></p> <p><i>The revised policy is attached to the proposed resolutions of the Board of Directors for the Annual General Meeting published on 26 March 2026 on the website www.luxempart.lu.</i></p>	<p>in favour <input type="checkbox"/> against <input type="checkbox"/> abstain <input type="checkbox"/></p>

Proposed resolutions	Voting instructions (Check the appropriate box, if applicable)
<p style="text-align: center;">18. Approval of the remuneration of the directors for the financial year 2026</p> <p>Proposed resolution:</p> <p><i>The Board of Directors proposes to the General Meeting to approve the remuneration of the members of the Board of Directors for the financial year 2026 as follows:</i></p> <p><i>Each member of the Board of Directors will be entitled to a fixed fee of € 50,000 per year. This indemnity is € 90,000 per year for the Vice-Chairman and € 180,000 per year for the Non-Executive Chairman.</i></p> <p><i>For each attendance in-person at a meeting of the Board of Directors, the directors will receive an attendance fee of € 3,500. In the event of a participation by telephone conference call, video conference, or any other similar means of communication, the attendance fee will be revised to € 2,500 per meeting. This fee amounts to € 7,000 for the Chairman, for each attendance in-person at a meeting of the Board of Directors, revised to € 5,000 for each attendance by telephone conference call, video conference, or any other similar means of communication.</i></p> <p><i>For each attendance in-person at a meeting of the Nomination and Remuneration Committee, of the Audit, Compliance and Risks Committee, and of the Sustainability Committee, the member of the relevant committee will receive an attendance fee of € 3,500. In the event of a participation by telephone conference call, video conference, or any other similar means of communication, the attendance fee will be revised to € 2,500 per meeting. This fee amounts to € 6,500 for the chair of the relevant committee for each attendance in-person at a meeting, revised to € 5,000 for each attendance by telephone conference call, video conference, or any other similar means of communication.</i></p>	<p style="text-align: center;">in favour <input type="checkbox"/> against <input type="checkbox"/> abstain <input type="checkbox"/></p>

Proposed resolutions	Voting instructions (Check the appropriate box, if applicable)
<p>19. Renewal of the mandate of the independent auditor for the financial year 2026</p> <p><i>Proposed resolution</i></p> <p><i>The Board of Directors proposes to the General Meeting to renew the mandate of KPMG Audit S.à r.l. as the Company's independent auditor (réviseur d'entreprises agréé) for the financial year ending December 31, 2026.</i></p>	<p>in favour <input type="checkbox"/> against <input type="checkbox"/> abstain <input type="checkbox"/></p>
<p>20. Miscellaneous</p> <p><i>No item.</i></p>	<p>No resolution</p>